- Home
- RFL vs CNTB Comparison
RFL vs CNTB Comparison
Compare RFL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- CNTB
- Stock Information
- Founded
- RFL 2017
- CNTB 2012
- Country
- RFL United States
- CNTB United States
- Employees
- RFL N/A
- CNTB N/A
- Industry
- RFL Real Estate
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- CNTB Health Care
- Exchange
- RFL Nasdaq
- CNTB Nasdaq
- Market Cap
- RFL 60.7M
- CNTB 54.4M
- IPO Year
- RFL N/A
- CNTB 2021
- Fundamental
- Price
- RFL $1.90
- CNTB $1.12
- Analyst Decision
- RFL
- CNTB Strong Buy
- Analyst Count
- RFL 0
- CNTB 2
- Target Price
- RFL N/A
- CNTB $7.50
- AVG Volume (30 Days)
- RFL 440.7K
- CNTB 107.0K
- Earning Date
- RFL 06-11-2025
- CNTB 05-15-2025
- Dividend Yield
- RFL N/A
- CNTB N/A
- EPS Growth
- RFL N/A
- CNTB N/A
- EPS
- RFL N/A
- CNTB N/A
- Revenue
- RFL $732,000.00
- CNTB $26,033,000.00
- Revenue This Year
- RFL N/A
- CNTB N/A
- Revenue Next Year
- RFL N/A
- CNTB N/A
- P/E Ratio
- RFL N/A
- CNTB N/A
- Revenue Growth
- RFL 35.56
- CNTB N/A
- 52 Week Low
- RFL $1.27
- CNTB $0.51
- 52 Week High
- RFL $3.19
- CNTB $1.60
- Technical
- Relative Strength Index (RSI)
- RFL 53.05
- CNTB 68.99
- Support Level
- RFL $1.81
- CNTB $1.02
- Resistance Level
- RFL $2.04
- CNTB $1.20
- Average True Range (ATR)
- RFL 0.16
- CNTB 0.08
- MACD
- RFL 0.00
- CNTB 0.01
- Stochastic Oscillator
- RFL 71.43
- CNTB 82.76
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.